Roth Capital Starts CymaBay Therapeutic (CBAY) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Stifel Nicolaus Starts CymaBay Therapeutic (CBAY) at Buy
September 17, 2014 6:40 AM EDTStifel Nicolaus initiated coverage on CymaBay Therapeutic (NASDAQ: CBAY) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on CymaBay Therapeutic click here. For more ratings news on CymaBay Therapeutic click here.
Shares of CymaBay Therapeutic closed at $7.37 yesterday.
... More